Skye Bioscience appoints Paul Grayson as Chairman; CEO Dhillon gets salary hike and stock options

Skye Bioscience, Inc.

Paul Grayson appointed Chairman effective Oct 25, 2024; CEO Punit Dhillon resigns as Chairman, remains on Board.
CEO Dhillon's base salary increased to $610,000; CFO Arsenault's to $450,000, effective Jan 1, 2025.
Stock options granted: Dhillon 650,000 shares, Arsenault 125,000 shares; 10-year term, 48-month vesting.
Grayson is independent director; currently CEO of Radionetics Oncology, former CEO of Tentarix and founder at Fate Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.